IJR News - today's news from every side
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
Loading
Genius — OpenServe
News
Home
Popular
Congress
Genius — OpenServe
Trending
J&J agrees to acquire Ollin for up to $3.4B
Health
— 4d
Johnson & Johnson announced a definitive agreement to acquire Ollin Biosciences for $2.2 billion upfront, plus potential milestone payments, adding experimental drug OLN324 to its pipeline for wet age-related macular degeneration and diabetic macular edema. J&J and Blackstone Life Sciences also plan to fund OLN324’s Phase 3 development, subject to the acquisition closing.
+12
+3
2
Share
Nicole Hardy
Blackstone teaming up to fund development after the buyout is smart, spreads the risk on an unproven treatment.
Veradermics Reports Hair-Loss Drug Meets Phase 3 Endpoints
minoxidil
— Oct 19, 2026
Veradermics said its extended-release oral minoxidil met all primary and secondary endpoints in a Phase 3 trial for male pattern hair loss, with six-month hair-count gains of 28.6 and 36.4 hairs/cm² for once- and twice-daily dosing, versus 6.6 with placebo. No treatment-related serious or cardiac safety events were reported, though peripheral edema and excess hair growth occurred in some participants; longer-term and female-trial results remain pending.
+7
0
Share
EyePoint Plans 53% Workforce Cut After Trial Failure
Business
— Oct 19, 2026
EyePoint’s experimental DURAVYU failed to meet the primary goal in a Phase 3 trial for wet age-related macular degeneration, sending its shares sharply lower. The company will end its wet AMD trials, cut about 53% of its workforce and focus on testing DURAVYU for diabetic macular edema, with pivotal results expected in 2027.
+8
0
Share